Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series

Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving tezepelumab treatment are presented.

Bibliographic Details
Published in:Journal of Allergy and Clinical Immunology: Global
Main Authors: Shigesato Inoue, MD, Hiroaki Ogata, MD, PhD, Yoichi Dotake, MD, Koichi Takagi, MD, PhD, Ayaka Shiota, MD, Yumiko Ishii, MD, PhD, Kentaro Tanaka, MD, PhD, Keiko Kan-o, MD, PhD, Hiromasa Inoue, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Subjects:
Asthma control
tezepelumab
rhinosinusitis
severe asthma
nasal polyps
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829325000499

Internet

http://www.sciencedirect.com/science/article/pii/S2772829325000499

Similar Items